Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Collaborator: Pfizer
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• DSM-IV-TR criteria for alcohol dependence disorder

• Age between 18 -65 years old.

• Score 7 or higher in the GHQ-28 scale.

Exclusion Criteria:

• More than 30 days without drinking alcohol.

• Severe medical disorders.

• Psychotic or bipolar disorders severely decompensated requiring antipsychotic medication.

• Opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week of detoxification treatment.

• Pregnant or lactating women